Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Daiichi Sankyo to Expand Sales Force in U.S. | Contract Pharma
Breaking News

Daiichi Sankyo to Expand Sales Force in U.S.

Daiichi Sankyo Co. Ltd. plans to more than double its U.S. sales staff in preparation for new drugs expected to come to market. According to a company statement, Daiichi Sankyo said it was also looking to expand its business through strategic investments, boost its European sales force and set up a new sales subsidiary in India.

U.S. medical representatives will be approximately 2,300 by the end of March 2010, up from 900. Sales staff at another U.S. unit will rise to 350 from 50. “The expansion of our sales base in the U.S. is an investment for the future as we have new products coming to market, ones that we expect to be major products,” said chief executive Takashi Shoda.

Among its new drug candidates are prasugrel, a blood-thinning drug being developed with Eli Lilly & Co., CS-8663, a combination drug of olmesartan or Benicar, and amlodipine, and its cholesterol-lowering drug Welchol also to be used to treat diabetes.

In addition to new drugs, the company plans to assume full control of Benicar sales after its co-promotion contract with Forest Laboratories ends in March 2008.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters